Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/202a3453a4724bdbaf304549fd75661f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Ejemplares similares